Dr. Hay’s research is focused on the central nervous system control of cardiovascular regulation. The primary emphasis is on understanding the biophysical and cellular mechanisms underlying neurotransmitter and hormone modulation of brainstem neurons and sympathetic outflow and, ultimately, how those actions affect arterial blood pressure and hypertension. Current efforts are focused are the development of novel neuroprotective peptide therapies for treatment of cognitive dysfunction in patients with cardiovascular disease. Dr. Hay’s recent discovery of a novel neuroprotective peptide has led to the creation of a new biotechnology company, ProNeurogen, Inc, where she currently serves as President, CEO and co-founder.